Dr. Bellmunt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215
Education & Training
Harvard Medical SchoolClass of 1982
Universidad de Barcelona Faculty of MedicineClass of 1982
Certifications & Licensure
MA State Medical License 2018 - 2025
Clinical Trials
- Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments Start of enrollment: 2024 Mar 05
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Perioperative cisplatin-based chemotherapy for muscle-invasive bladder cancer: a decision analysis.Luca Afferi, Beate Jahn, Amar H Kelkar, Stijntje W Dijk, Zach M Feldman
World Journal of Urology. 2025-03-30 - Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab.Lorena Incorvaia, Sarah Scagliarini, Fernando Sabino Marques Monteiro, Hideki Takeshita, Jose Carlos Tapia
Scientific Reports. 2025-03-14 - Impact of DNA repair deficiency on sensitivity to antibody-drug conjugate (ADC) payloads in bladder cancer.Surish P Shanmugam, Yuzhen Zhou, Isabella Stelter, Timothy Hanlon, Raie T Bekele
Bladder Cancer. 2025-02-21
Press Mentions
Machine Learning Uncovers Complexity of Immunotherapy Variables in Bladder CancerMarch 10th, 2025- Revolutionary Data Analysis Enhances Insights into Immunotherapy MechanismsFebruary 20th, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
